Pathophysiological impacts of exposure to an endocrine disruptor (tetradifon) on α-amylase and lipase activities associated metabolic disorders.

We have investigated the effect of subchronic exposure to tetradifon (TDF), as an endocrine disruptor chemical, on some parameters related to serious metabolomic disorders such as obesity, type 2 diabetes and hyperlipidemia. TDF promoted significant increases in both duodenal and pancreatic α-amylase and lipase especially in the 12-weeks treated rats. Plasmatic glucose and lipid profile; total cholesterol (T-cholesterol), low density lipoprotein-cholesterol (LDL-c), high-density lipoprotein-cholesterol (HDL-c) and glyceride, were markedly disrupted. Compared with controls, biochemical liver injury parameters: aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) and lactate dehydrogenase (LDH) were significantly increased. Moreover, notable pathological features were reported in liver tissues. These results confirm a strong relationship between exposure to an endocrine disruptor and metabolic disorders. In fact, subchronic exposure to TDF lead to lipidemic and glycemic disruption associated hyperactivity in both α-amylase and lipase. Overall, these disruptions could be an important step on the pathway to metabolic pathology.